Safety and tolerability of the BNT111 mRNA vaccine, which encodes four melanoma antigens: NY-ESO-1, tyrosinase, MAGE-A3, and TPTE, is under evaluation in a phase I trial (NCT02410733). This evidence concerns the gene TYR and melanoma.